After enjoying a 20% rise in sales to £12.5m in 2024, we are now setting our sights on adding an additional £5m in revenue over the next 12 months, with the management team also hinting at the possibility of embarking on a major acquisition push.
Marketing & Strategy Director Katy O’Keeffe said: “Our outlook for 2025 is highly promising, driven by a robust pipeline that combines the expansion of our own product portfolio with organic growth opportunities in contract manufacturing.
“A significant number of clients, whose sales have been stable year-on-year, have displayed strong increases, most noticeably our TIVATEK product range, which we sell into the NHS via a distributor. The products we manufacture ourselves have also enjoyed a 33% rise, so you can begin to understand why we are looking at getting close to £20m for the first time in our history.”
The next chapter
From our state-of-the-art production facility, we are focused on helping medical device and healthcare businesses commercialise new technology, with our recent success stories featuring a home dialysis machine, a patient friendly and easy-to-use breath operated inhaler, and a bio-artificial liver.
Thanks to the vast regulatory approvals Europlaz holds, we also manufacture our own product ranges, including neonatal flow sensors that are due to be trialled with Barts Health NHS Trust in London shortly.
Europlaz Commercial Director Rory O’Keeffe added: “Regulatory services is another key growth area, as an increasing number of customers depend on us to navigate the complex and stringent Medical Device Regulation requirements. Our expertise in this area positions us as a trusted partner in ensuring compliance and market readiness.
“Acquisitions are something we are also looking at strongly. The ideal purchase for us would be a firm that expands our medical product range, which we currently sell directly in the UK and internationally.
“By diversifying our portfolio, we can distribute the astronomical costs of annual surveillance across multiple product ranges, resulting in improved cost-efficiency and sustainability for us and our clients.”
From R&D to reality
Europlaz does not design products, instead our most successful partnerships are with world-class design specialists who take products from proof of concept through design and usability phases. We have invested more than £3.5m into R&D and production capability to reinforce this reputation, and this drives design for manufacturing and industrialisation, ensuring that the product reaches patients efficiently and effectively.
Katy concluded: “We are probably one of Essex’s best-kept secrets, but this is slowly beginning to change. Europlaz is manufacturing products that save lives or make treatment better and this, alongside our commitment to sustainability, is something we are passionate about.
“2025 is going to be an exciting year for our business as we capitalise on a mix of our own products, new contract manufacturing wins and the possibility of our first acquisition.”
To keep up to date with latest from Europlaz, you can follow us on LinkedIn.